Merck Sees $1.17M in Unusual Call Activity Even as Shares Slide 2.45% Tuesday

By TrendSpider Editor

Two unusual call contracts totaling $1,172,071.60 in premium hit the tape for Merck & Company, Inc. on Tuesday, signaling that at least some traders are positioning for a meaningful recovery despite the stock falling 2.45% to $141.88 on the session. The dominant trade, a 1,600-lot call sweep at the

Merck Sees $1.17M in Unusual Call Activity Even as Shares Slide 2.45% Tuesday

Two unusual call contracts totaling $1,172,071.60 in premium hit the tape for Merck & Company, Inc. on Tuesday, signaling that at least some traders are positioning for a meaningful recovery despite the stock falling 2.45% to $141.88 on the session. The dominant trade, a 1,600-lot call sweep at the $170 strike expiring June 17, 2027, accounted for the overwhelming majority of that premium at $1,136,000. With MRK trading near the upper half of its 52-week range of $82.04 to $156.92, the bullish positioning stands out against the backdrop of today's weakness.

Key Drivers of the MRK Stock Move

• Main Catalyst: Two unusual call contracts were flagged on Tuesday. The first is a 62-contract call at the $145 strike expiring November 6, 2026, carrying $36,071.60 in premium and an open interest reading of 221% above normal. The second and far larger trade is a 1,600-contract call at the $170 strike expiring June 17, 2027, with $1,136,000 in premium and open interest at 88% of existing levels.
• Bull Case: The $170 strike call expiring in June 2027 represents a significant out-of-the-money bet that Merck shares could rally more than 19.8% from current levels within roughly eight months. The sheer size of the 1,600-contract position and $1,136,000 in premium committed suggest a high-conviction directional trade rather than routine hedging activity.
• Bear Case: MRK is already trading below its 52-week high of $156.92, meaning the $170 strike call is deeply out of the money and would require a move to new multi-year highs just to approach profitability at expiration. Today's 2.45% decline also reflects near-term selling pressure that could persist, working against shorter-dated positioning like the November $145 call.

The forward setup for Merck presents a mixed picture. The longer-dated June 2027 call suggests that whoever placed that trade is looking past near-term turbulence and expecting a sustained recovery or a catalyst-driven breakout over the next several quarters. The November $145 call, expiring in roughly three and a half weeks, sits at the money relative to near-term price action and benefits from the elevated open interest reading of 221%, pointing to activity well above what was already outstanding in that contract. Merck has faced persistent headline risk around pricing pressures and competition in its core oncology and vaccine franchises, so any positive clinical or pipeline news between now and June 2027 could validate the larger bullish bet. Traders watching MRK should monitor volume and open interest development in the $170 strike over coming sessions to determine whether this is a single institutional position or the start of broader accumulation.

MRK Unusual Options Activity

• Type: Call | Strike: $145 | Expiry: November 6, 2026 | Volume: 62 contracts | Open Interest: 221% of normal
• Type: Call | Strike: $170 | Expiry: June 17, 2027 | Volume: 1,600 contracts | Open Interest: 88% of existing levels

Both flagged contracts are calls, meaning all unusual flow detected Tuesday leaned bullish. Total premium across the two contracts reached $1,172,071.60, with the June 2027 $170 strike representing 96.9% of that total outlay.

MRK Seasonality

October has historically been a transitional month for large-cap pharmaceutical names, with fourth-quarter positioning often picking up ahead of year-end earnings and pipeline readouts. A June 2027 expiry gives the position time to capture any data or regulatory events that could materialize through the first half of next year.

MRK Relative Performance

MRK's 2.45% decline on Tuesday places it as an underperformer relative to the broader large-cap healthcare sector on the session. Trading at $141.88, the stock sits well above its 52-week low of $82.04, reflecting a strong recovery over the past year, but it remains below its 52-week high of $156.92, leaving roughly $15 of overhead supply between current levels and recent peak resistance.